Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sponsor: Genentech, Inc.
Summary
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Official title: A Phase II, Randomized, Double-Masked, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of RO7965032 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
321
Start Date
2026-09-30
Completion Date
2030-08-21
Last Updated
2026-10-01
Healthy Volunteers
No
Interventions
RO7965032
RO7965032 will be administered as per the schedule defined in the protocol.
Placebo
Placebo will be administered as per the schedule defined in the protocol.